Advertisement

Inflammation

pp 1–15 | Cite as

Application of Deacetylated Poly-N-Acetyl Glucosamine Nanoparticles for the Delivery of miR-126 for the Treatment of Cecal Ligation and Puncture-Induced Sepsis

  • Joy N. Jones Buie
  • Yue Zhou
  • Andrew J. Goodwin
  • James A. Cook
  • John Vournakis
  • Marina Demcheva
  • Ann-Marie Broome
  • Suraj Dixit
  • Perry V. Halushka
  • Hongkuan Fan
ORIGINAL ARTICLE

Abstract

Sepsis is an acute inflammatory syndrome in response to infection. In some cases, excessive inflammation from sepsis results in endothelial dysfunction and subsequent increased vascular permeability leading to organ failure. We previously showed that treatment with endothelial progenitor cells, which highly express microRNA-126 (miR-126), improved survival in mice subjected to cecal ligation and puncture (CLP) sepsis. miRNAs are important regulators of gene expression and cell function, play a major role in endothelial homeostasis, and may represent an emerging therapeutic modality. However, delivery of miRNAs to cells in vitro and in vivo is challenging due to rapid degradation by ubiquitous RNases. Herein, we developed a nanoparticle delivery system separately combining deacetylated poly-N-acetyl glucosamine (DEAC-pGlcNAc) polymers with miRNA-126-3p and miRNA-126-5p and testing these combinations in vitro and in vivo. Our results demonstrate that DEAC-pGlcNAc polymers have an appropriate size and zeta potential for cellular uptake and when complexed, DEAC-pGlcNAc protects miRNA from RNase A degradation. Further, DEAC-pGlcNAc efficiently encapsulates miRNAs as evidenced by preventing their migration in an agarose gel. The DEAC-pGlcNAc-miRNA complexes were taken up by multiple cell types and the delivered miRNAs had biological effects on their targets in vitro including pERK and DLK-1. In addition, we found that delivery of DEAC-pGlcNAc alone or DEAC-pGlcNAc:miRNA-126-5p nanoparticles to septic animals significantly improved survival, preserved vascular integrity, and modulated cytokine production. These composite studies support the concept that DEAC-pGlcNAc nanoparticles are an effective platform for delivering miRNAs and that they may provide therapeutic benefit in sepsis.

KEY WORDS

Endothelial dysfunction Polymicrobial sepsis miRNA delivery Organ dysfunction Inflammation 

Notes

Acknowledgements

We thank Ametria Harrison and Pengfei Li for their technical support throughout this project. Additionally, we thank Robin Muise-Helmericks and Amanda LaRue for their experimental expertise and project support.

Funding

This work was supported by the NIGMS 1R01GM113995 (HF). This work was also supported by grants NHLBI 5T32HL007260–39 (JJB), 1K23HL135263-01A1 (AG), and UL1 TR 001450 (PVH), and financial and technical supports were provided in part by Marine Polymer Sciences, Inc. Burlington, MA (JV and MD).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

Animal studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee at the Medical University of South Carolina.

References

  1. 1.
    Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer, 2011: Statistical Brief #160. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD), 2006.Google Scholar
  2. 2.
    Murphy, S.L., J. Xu, and K.D. Kochanek. 2013. Deaths: final data for 2010. National Vital Statistics Reports 61: 1–117.PubMedGoogle Scholar
  3. 3.
    Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013: Statistical Brief #204. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD), 2006.Google Scholar
  4. 4.
    Angus, D.C., and T. van der Poll. 2013. Severe sepsis and septic shock. The New England Journal of Medicine 369: 2063.CrossRefGoogle Scholar
  5. 5.
    Pratt, A.J., and I.J. MacRae. 2009. The RNA-induced silencing complex: a versatile gene-silencing machine. The Journal of Biological Chemistry 284: 17897–17901.CrossRefGoogle Scholar
  6. 6.
    Neth, P., M. Nazari-Jahantigh, A. Schober, and C. Weber. 2013. MicroRNAs in flow-dependent vascular remodelling. Cardiovascular Research 99: 294–303.CrossRefGoogle Scholar
  7. 7.
    Chistiakov, D.A., A.N. Orekhov, and Y.V. Bobryshev. 2016. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. Journal of Molecular and Cellular Cardiology 97: 47–55.CrossRefGoogle Scholar
  8. 8.
    Wang, S., A.B. Aurora, B.A. Johnson, X. Qi, J. McAnally, J.A. Hill, J.A. Richardson, R. Bassel-Duby, and E.N. Olson. 2008. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Developmental Cell 15: 261–271.CrossRefGoogle Scholar
  9. 9.
    Fish, J.E., M.M. Santoro, S.U. Morton, S. Yu, R.F. Yeh, J.D. Wythe, K.N. Ivey, B.G. Bruneau, D.Y.R. Stainier, and D. Srivastava. 2008. miR-126 regulates angiogenic signaling and vascular integrity. Developmental Cell 15: 272–284.CrossRefGoogle Scholar
  10. 10.
    Kuhnert, F., M.R. Mancuso, J. Hampton, K. Stankunas, T. Asano, C.Z. Chen, and C.J. Kuo. 2008. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 135: 3989–3993.CrossRefGoogle Scholar
  11. 11.
    Tang, R., L. Pei, T. Bai, and J. Wang. 2016. Down-regulation of microRNA-126-5p contributes to overexpression of VEGFA in lipopolysaccharide-induced acute lung injury. Biotechnology Letters 38: 1277–1284.CrossRefGoogle Scholar
  12. 12.
    Fan, H., A.J. Goodwin, E. Chang, B. Zingarelli, K. Borg, S. Guan, P.V. Halushka, and J.A. Cook. 2014. Endothelial progenitor cells and a stromal cell-derived factor-1alpha analogue synergistically improve survival in sepsis. American Journal of Respiratory and Critical Care Medicine 189: 1509–1519.CrossRefGoogle Scholar
  13. 13.
    Goodwin, A.J., C. Guo, J.A. Cook, B. Wolf, P.V. Halushka, and H. Fan. 2015. Plasma levels of microRNA are altered with the development of shock in human sepsis: an observational study. Critical Care 19: 440.CrossRefGoogle Scholar
  14. 14.
    Zhou, Y., P. Li, A.J. Goodwin, J.A. Cook, P.V. Halushka, E. Chang, and H. Fan. 2018. Exosomes from endothelial progenitor cells improve the outcome of a murine model of sepsis. Molecular Therapy 26: 1375–1384.CrossRefGoogle Scholar
  15. 15.
    Schober, A., M. Nazari-Jahantigh, Y. Wei, K. Bidzhekov, F. Gremse, J. Grommes, R.T.A. Megens, K. Heyll, H. Noels, M. Hristov, S. Wang, F. Kiessling, E.N. Olson, and C. Weber. 2014. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nature Medicine 20: 368–376.CrossRefGoogle Scholar
  16. 16.
    Juliano, R.L., R. Alam, V. Dixit, and H.M. Kang. 2009. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology 1: 324–335.CrossRefGoogle Scholar
  17. 17.
    Vournakis JN, Finkielsztein S, Pariser ER, Helton M. Bicompatible poly-β-1→4-N-acetylglucosamine. Google Patents, 2004.Google Scholar
  18. 18.
    Lindner, H.B., A. Zhang, J. Eldridge, M. Demcheva, P. Tsichlis, A. Seth, et al. 2011. Anti-bacterial effects of poly-N-acetyl-glucosamine nanofibers in cutaneous wound healing: requirement for Akt1. PLoS One 6: e18996.CrossRefGoogle Scholar
  19. 19.
    Lindner, H.B., L.M. Felmly, M. Demcheva, A. Seth, R. Norris, A.D. Bradshaw, et al. 2015. pGlcNAc nanofiber treatment of cutaneous wounds stimulate increased tensile strength and reduced scarring via activation of Akt1. PLoS One 10: e0127876.CrossRefGoogle Scholar
  20. 20.
    Kong, X.Y., Y.Q. Du, L. Li, J.Q. Liu, G.K. Wang, J.Q. Zhu, et al. 2010. Plasma miR-216a as a potential marker of pancreatic injury in a rat model of acute pancreatitis. World Journal of Gastroenterology : WJG 16: 4599–4604.CrossRefGoogle Scholar
  21. 21.
    Zhou, F., X. Jia, Y. Yang, Q. Yang, C. Gao, S. Hu, Y. Zhao, Y. Fan, and X. Yuan. 2016. Nanofiber-mediated microRNA-126 delivery to vascular endothelial cells for blood vessel regeneration. Acta Biomaterialia 43: 303–313.CrossRefGoogle Scholar
  22. 22.
    Eliyahu, H., Y. Barenholz, and A.J. Domb. 2005. Polymers for DNA delivery. Molecules 10: 34–64.CrossRefGoogle Scholar
  23. 23.
    Bamrungsap, S., Z. Zhao, T. Chen, L. Wang, C. Li, T. Fu, and W. Tan. 2012. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine (London, England) 7: 1253–1271.CrossRefGoogle Scholar
  24. 24.
    Narasimhan, P., J. Liu, Y.S. Song, J.L. Massengale, and P.H. Chan. 2009. VEGF stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke 40: 1467–1473.CrossRefGoogle Scholar
  25. 25.
    Gavard, J., and J.S. Gutkind. 2006. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nature Cell Biology 8: 1223–1234.CrossRefGoogle Scholar
  26. 26.
    Hao, D., W. Xiao, R. Liu, P. Kumar, Y. Li, P. Zhou, F. Guo, D.L. Farmer, K.S. Lam, F. Wang, and A. Wang. 2017. Discovery and characterization of a potent and specific peptide ligand targeting endothelial progenitor cells and endothelial cells for tissue regeneration. ACS Chemical Biology 12: 1075–1086.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Joy N. Jones Buie
    • 1
  • Yue Zhou
    • 1
    • 2
  • Andrew J. Goodwin
    • 3
  • James A. Cook
    • 4
  • John Vournakis
    • 5
  • Marina Demcheva
    • 5
  • Ann-Marie Broome
    • 4
    • 6
  • Suraj Dixit
    • 6
  • Perry V. Halushka
    • 7
    • 8
  • Hongkuan Fan
    • 1
    • 9
  1. 1.Department of Pathology and Laboratory MedicineMedical University of South CarolinaCharlestonUSA
  2. 2.Department of Biopharmaceutics College of PharmacyNanjing University of Chinese MedicineNanjingChina
  3. 3.Department of Pulmonary, Critical Care, Allergy, and Sleep MedicineMedical University of South CarolinaCharlestonUSA
  4. 4.Department of NeurosciencesMedical University of South CarolinaCharlestonUSA
  5. 5.Marine Polymer Technologies, Inc.BurlingtonUSA
  6. 6.Department of Cell & Molecular Pharmacology and Experimental TherapeuticsMedical University of South CarolinaCharlestonUSA
  7. 7.Department of MedicineMedical University of South CarolinaCharlestonUSA
  8. 8.Department of PharmacologyMedical University of South CarolinaCharlestonUSA
  9. 9.Department of Regenerative Medicine and Cell BiologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations